Clinical Therapeutics/New Technology-Oral Agents

Clinical Therapeutics/New Technology-Oral Agents

Open Access
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Bernard Zinman, Vanita R. Aroda, John B. Buse, Bertrand Cariou, Stewart B. Harris, Søren Tetens Hoff, Karen Boje Pedersen, Mads Jeppe Tarp-Johansen, Eiichi Araki

Diabetes Care Dec 2019, 42 (12) 2262-2271; DOI: 10.2337/dc19-0898
Open Access
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard, Julio Rosenstock, Luis H. Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Østergaard Lindberg, Ildiko Lingvay, Anette Luther Søndergaard, Marianne Bach Treppendahl, Eduard Montanya

Diabetes Care Dec 2019, 42 (12) 2272-2281; DOI: 10.2337/dc19-0883
You have access
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi, Yuksel Altuntas, Nebojsa M. Lalic, Enrique C. Morales Villegas, Ole K. Jeppesen, Erik Christiansen, Christin L. Hertz, Martin Haluzík

Diabetes Care Sep 2019, 42 (9) 1724-1732; DOI: 10.2337/dc19-0749
You have access
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes
Bruce A. Perkins, Julio Rosenstock, Jay S. Skyler, Lori M. Laffel, David Z. Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T. George, Jan Marquard, Nima Soleymanlou

Diabetes Care Sep 2019, 42 (9) 1716-1723; DOI: 10.2337/dc19-0548
You have access
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Julio Rosenstock, Christopher H. Sorli, Michael E. Trautmann, Cristóbal Morales, Ulrich Wendisch, George Dailey, Marcus Hompesch, In Young Choi, Jahoon Kang, John Stewart, Kun-Ho Yoon

Diabetes Care Sep 2019, 42 (9) 1733-1741; DOI: 10.2337/dc18-2648
You have access
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program
Thomas Danne, Bertrand Cariou, John B. Buse, Satish K. Garg, Julio Rosenstock, Phillip Banks, Jake A. Kushner, Darren K. McGuire, Anne L. Peters, Sangeeta Sawhney, Paul Strumph

Diabetes Care May 2019, 42 (5) 919-930; DOI: 10.2337/dc18-2149
You have access
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
Aino Latva-Rasku, Miikka-Juhani Honka, Joel Kullberg, Nina Mononen, Terho Lehtimäki, Juha Saltevo, Anna K. Kirjavainen, Virva Saunavaara, Patricia Iozzo, Lars Johansson, Jan Oscarsson, Jarna C. Hannukainen, Pirjo Nuutila

Diabetes Care May 2019, 42 (5) 931-937; DOI: 10.2337/dc18-1569
You have access
Importance of Treatment Status in Links Between Type 2 Diabetes and Alzheimer’s Disease
Elissa C. McIntosh, Daniel A. Nation

Diabetes Care May 2019, 42 (5) 972-979; DOI: 10.2337/dc18-1399
Open Access
The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
Daniël H. van Raalte, Petter Bjornstad, Frederik Persson, David R. Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J.L. Heerspink, David Cherney

Diabetes Care Oct 2019, 42 (10) 1921-1929; DOI: 10.2337/dc19-0937
You have access
Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus
Thea Anine Strøm Halden, Kine Eide Kvitne, Karsten Midtvedt, Laavanyaah Rajakumar, Ida Robertsen, Jan Brox, Jens Bollerslev, Anders Hartmann, Anders Åsberg, Trond Jenssen

Diabetes Care Jun 2019, 42 (6) 1067-1074; DOI: 10.2337/dc19-0093

Main menu

User menu

Search

Clinical Therapeutics/New Technology-Oral Agents

Pages

Navigate

More Information

Other ADA Resources